ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Cellular Biomedicine Announces First Patient Dosing in Anti-CD20 Trial
June 20, 2019Cellular Biomedicine Group has initiated its Phase I Clinical Trial of anti-CD20 Chimeric Antigen Receptor T-cell (CAR-T) targeting anti-CD19 treated, relapsed diffuse large B-cell lymphoma (DLBCL) and small B-cell lymphoma patients in China, and dosed th -
Novartis collaborates with Cellular Biomedicine for CAR-T Therapy
September 29, 2018Novartis will be the exclusive holder of the marketing license.
Pharma Sources Insight January 2025
